Inactivated Jak–STAT signaling pathway may serve as an effective therapeutic strategy in growth inhibition of SP/CD44 + tumorigenic cells in Akt/β-catenin–driven HCC (Toh et al., 2020). Here, AKT1 is linked to hepatocellular carcinoma.